Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study

Background: Vaccination is a promising strategy to protect vulnerable groups like inflammatory bowel disease (IBD) patients against COVID-19 and associated severe outcomes. COVID-19 vaccine clinical trials excluded IBD patients taking infliximab with azathioprine or 6-mercaptopurine (infliximab comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Shehab, Mohammad, Abu-Farha, Mohamed, Alrashed, Fatema, Alfadhli, Ahmad, Alotaibi, Khazna, Alsahli, Abdullah, Alphonse Thanaraj, Thangavel, Channanath, Arshad, Ali, Hamad, Abubaker, Jehad, Almulla, Fahd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623980/
https://www.ncbi.nlm.nih.gov/pubmed/34830644
http://dx.doi.org/10.3390/jcm10225362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623980/
https://www.ncbi.nlm.nih.gov/pubmed/34830644
http://dx.doi.org/10.3390/jcm10225362

Ejemplares similares